Dermira Inc. (NASDAQ:DERM) Director William R. Ringo sold 500 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $34.25, for a total transaction of $17,125.00. Following the transaction, the director now owns 500 shares in the company, valued at approximately $17,125. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Dermira Inc. (NASDAQ:DERM) opened at 35.04 on Thursday. The firm’s market capitalization is $1.24 billion. Dermira Inc. has a 52-week low of $17.42 and a 52-week high of $36.16. The firm has a 50-day moving average of $33.12 and a 200-day moving average of $29.46.
Dermira (NASDAQ:DERM) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities research analysts forecast that Dermira Inc. will post ($3.39) EPS for the current fiscal year.
A number of analysts recently weighed in on DERM shares. Zacks Investment Research raised shares of Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, June 14th. Needham & Company LLC reissued a “buy” rating and issued a $46.00 target price on shares of Dermira in a research note on Wednesday, June 22nd. Finally, Leerink Swann reissued a “buy” rating on shares of Dermira in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $41.00.
A number of hedge funds have recently made changes to their positions in DERM. TimesSquare Capital Management LLC boosted its stake in Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock worth $72,877,000 after buying an additional 1,101,645 shares in the last quarter. FMR LLC boosted its stake in Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock worth $118,847,000 after buying an additional 921,800 shares in the last quarter. Jennison Associates LLC boosted its stake in Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock worth $73,539,000 after buying an additional 860,597 shares in the last quarter. Loomis Sayles & Co. L P bought a new stake in Dermira during the second quarter worth about $10,678,000. Finally, Vanguard Group Inc. boosted its stake in Dermira by 47.9% in the second quarter. Vanguard Group Inc. now owns 941,164 shares of the biopharmaceutical company’s stock worth $27,529,000 after buying an additional 304,750 shares in the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.